Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pulmonology Exam > Asthma & COPD > Flashcards

Asthma & COPD Flashcards

1
Q

obstructive lung diseases: diseases with narrowing of airways

A

*COPD
*asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

obstructive lung diseases: diseases with DILATION of airways

A

*cystic fibrosis (CF)
*non-CF bronchiectasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

asthma - defined

A

*a disease of CHRONIC inflammation of the airways
*intermittent obstructive lung disease often triggered by allergens, viral URIs, and stress

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

asthma - variable symptoms

A

*variable and recurring dyspnea, wheezing, cough, and/or chest tightness
*reversible airflow obstruction (bronchodilator response)
*resolution of an exacerbation
*diurnal symptoms (worse symptoms at night) frequently present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

bronchodilator reversibility in asthma

A

*obstruction is reversed with the use of a bronchodilator, defined by:
an increase in FEV1 or FVC by 10% predicted or more after use of a bronchodilator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

asthma phenotypes

A

*Th2 asthma (allergic asthma)
*non-Th2 asthma (non-allergic asthma)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

allergic asthma (Th2): features

A

*atopic (rhinitis, eczema, asthma)
*allergens: dust mites, seasonal pollens, pet dander
*occupational asthma: workplace allergens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

allergic asthma: pathobiology

A

*Th2-driven pathobiology: allergen → stimulates an antigen presenting cell → activates Th2 cells, which release IL-4, IL-5, IL-13 → activation of eosinophils, mast cells, and B cells → release of leukotrienes, histamine, etc

*leads to atopic phenotype
*eosinophils, mast cells, and B cells are the MAIN EFFECTOR CELLS
*UNCONTROLLED INFLAMMATION LEADS TO AIRWAY REMODELING

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

airway inflammation in allergic asthma

A

*inflammation of terminal bronchioles (smooth muscles, no cartilage)
*Th2 cells are activated by an antigen → release of IL-2, IL-4, IL-5, and IL-13 → activation of eosinophils, mast cells, and IgE from B cells
*bronchial submucosal edema and smooth muscle contraction
*bronchial obstruction from edema, cellular debris, airway smooth muscle hypertrophy, bronchospasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

hypersensitivity in allergic asthma

A

*chronic underlying inflammation of asthma: type IV Th2 hypersensitivity
*acute exacerbation of asthma is acute inflammation in addition to chronic inflammation: type 1 (IgE-mediated) hypersensitivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

non-allergic asthma (non-Th2): features

A

*common triggers: viral infections, cold air, exercise, sinusitis, gastric reflux, stress
*inhaled irritants: tobacco, solvents, chemicals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

non-allergic asthma: pathobiology

A

*not entirely known
*triggers are not allergens (they are something else)
*NEUTROPHILS play a key role as an effector cell
*uncontrolled inflammation leads to airway remodeling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

airway remodeling due to chronic inflammation

A

*smooth muscle hypertrophy & hyperplasia
*goblet cell hyperplasia
*combined, these hypertrophies cause a narrowed lumen, causing OBSTRUCTION of airflow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

diagnosis of asthma: testing airway responsiveness

A

*assess bronchial responsiveness to see how the airways “respond” to stimuli using:
1. short-acting beta agonist (bronchodilator): responsive = 10%+ increase in FEV1 or FVC
2. bronchoprovocation to induce hyper-responsiveness by: short-acting cholinergic (e.g. methacholine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

classic asthma symptoms

A

EPISODIC symptoms of:
1. COUGH (esp after exertion, breathing cold air, at night, after colds, paroxysmal)
2. WHEEZING (chest tightness, noisy breathing)
3. BREATHLESSNESS (esp if intermittent, after exertion, or at night)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

physical exam: asthma (during acute exacerbation)

A

*tachypnea
*use of accessory muscles to breathe
*markedly prolonged expiration with wheezing
*no air movement, “silent chest”
*intercostal retractions in childen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

lab studies & pathology for workup of asthma

A

*CBC (looking for eosinophilia)
*allergy testing
*sputum samples:
-Cruschmann spirals (mucous plugs from epithelium)
-Charcot-Leyden crystals (eosinophilic crystals)
-Creola bodies (desquamated epithelial cells)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

CXR findings in asthma

A

*CXR rarely demonstrates any abnormalities in asthma
*advanced disease from airway remodeling or acute exacerbation can cause hyperinflation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

asthma therapies: short-acting beta agonists (SABA)

A

*used for RESCUE (sudden onset symptoms)
*examples: albuterol, levalbuterol, pirbuterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

asthma therapies: inhaled corticosteroids

A

*goal: target underlying inflammation (maybe prevent airway remodeling)
*examples: fluticasone, budesonide, mometasone, flunisolide, etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

asthma therapies: leukotriene modifier therapies

A

*Montelukast [a leukotriene (LTD4) receptor (CysLT1) antagonist)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

asthma therapies: biologic therapies for severe eosinophilic asthma

A

*monoclonal antibodies (omalizumab, reslizumab, mepolizumab, benralizumab)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

aspirin-induced asthma

A

*patient with a history of asthma takes aspirin
*aspirin inhibits COX-1
*less COX-1 activity → decreased arachidonic acid metabolism via COX → less PGE2 (anti-inflammatory)
*increase in leukotrienes and more inflammation of the submucosa
*increased bronchial constriction/hyper-responsiveness

24
Q

status asthmaticus - overview

A

*extreme, life-threatening asthma exacerbation
*does NOT respond to bronchodilators

25
Q

status asthmaticus - clinical features

A

*tachypnea, hypoxemia, cyanosis
*signs of respiratory arrest, pulsus paradoxus (exaggerated drop in systolic BP with inspiration)

26
Q

status asthmaticus - diagnosis

A

*CBC (look for infection)
*arterial blood gas (look for increased PCO2, hypoxemia, low pH)
*peak expiratory flow measurement (FEV1 < 50% warrants ICU admission)
*CXR
*EKG

27
Q

status asthmaticus - management

A

*bronchodilation
*systemic steroids
*IV magnesium
*O2
*non-invasive ventilation or intubation
*INDICATIONS OF INTUBATION: NORMALIZATION OF PCO2 (PCO2 starts low, but then starts rising/becomes elevated)

28
Q

chronic obstructive pulmonary disease (COPD) - risk factors

A

*SMOKING
*genetic etiologies
*other

29
Q

chronic obstructive pulmonary disease (COPD) - definition

A

*characterized by PERSISTENT (CHRONIC) AIRFLOW OBSTRUCTION [FEV1/FVC is < 0.70]
*frequently progressive and disabling
*associated with a chronic inflammatory response in airways/lungs to noxious particles or gases
*damage to small airways

30
Q

chronic obstructive pulmonary disease (COPD) - phenotypes

A
  1. chronic bronchitis
  2. emphysema
31
Q

PFT findings in COPD

A

*FEV1/FVC: < 0.7 or less than LLN
*FVC: normal or decreased
*FEV1: DECREASED (used to determine severity of disease)
*RV: increased if air trapping is present
*TLC: normal or increased
*DLCO: normal (chronic bronchitis) vs. decreased (emphysema)
*NO reversal of obstruction with bronchodilator

32
Q

DLCO PFT findings of COPD: chronic bronchitis vs. emphysema

A

*if DLCO is normal: chronic bronchitis
*if DLCO is decreased: emphysema

33
Q

pathophysiology of COPD

A

*COPD is a disease of chronic inflammation
*increased NEUTROPHILS, macrophages, and lymphocytes
*goblet cell hyperplasia
*hypersecretion and impaired ciliary function
*smooth muscle hyperplasia
*loss of parenchyma (in emphysema - due to unopposed proteases)

34
Q

COPD: chronic bronchitis - overview & clinical definition

A

*“blue bloaters”
*defined by: sputum production most days for 3 months for 2 consecutive years of more (excessive mucociliary dysfunction, increased goblet cell secretion)
*most commonly caused by smoking

35
Q

COPD: chronic bronchitis - mechanism

A

*progressive obstruction → hypoventilation and V/Q mismatch → progressive respiratory acidosis and hypoxemia (BLUE)
*alveolar hypoventilation → pulmonary artery vasoconstriction → right heart failure (cor pulmonale) → fluid retention (BLOATER)

36
Q

COPD: chronic bronchitis - Reid index

A

*ratio between the thickness of the submucosal mucous secreting glands and the thickness between the epithelium and the cartilage
*ratio > 0.4 is consistent with chronic bronchitis

37
Q

COPD: emphysema - overview and clinical definition

A

*“pink puffers”
*defined by: destruction of alveoli, alveolar duct, and/or respiratory bronchioles
*DECREASED DLCO on PFTs
*INCREASED COMPLIANCE due to loss of elastic fibers and less lung recoil
*leads to barrel chest, air trapping, and hyperinflation

38
Q

COPD: emphysema - mechanism

A

*alveolar macrophages release proteases and cytokines → recruit neutrophils secrete elastase and proteases
*both terminal bronchioles/alveoli with associated capillary beds destroyed
*match V/Q deficit: HYPOXEMA & HYPERCAPNIA
*attempts hyperventilation due to hypercapnia → air trapping develops and decreased cardiac output → increasing V/Q mismatch (poor perfusion in areas of good ventilation)
*cachexia is mutifactorial: hyperventilation, increased work of breathing (PINK PUFFER), inflammatory cytokines

39
Q

COPD: emphysema - 2 locations

A
  1. centrilobular/centriacinar emphysema (occurs in respiratory bronchioles)
  2. panlobular/panacinar emphysema (occurs in alveoli/alveolar ducts)
40
Q

centrilobular emphysema

A

*emphysema in the respiratory bronchioles (spares distal alveoli)
*associated with SMOKING
*commonly affects the upper lobes

41
Q

panlobular emphysema

A

*emphysema in the alveoli/alveolar ducts
*associated with A1AT (alpha1-antitrypsin deficiency)
*commonly affects the lower lobes

42
Q

chronic hypercapnic respiratory failure in COPD

A

*to maintain minute ventilation early in the disease, patients will take large tidal volumes and have a prolonged expiratory phase (due to obstruction)
*hypercapnia is due to INCREASED DEAD SPACE, which happens because of:
-as the disease progresses, air trapping occurs due to obstruction of the small airways and progressive worsening of FEV1; air is trapped in the alveoli, but its not well exchanged (ventilated) during respiration
-this leads to an overall decrease in tidal volume with a max respiratory rate, but the alveolar minute ventilation is inadequate → chronic hypercapnic respiratory failure

43
Q

COPD - clinical presentation

A

*DYSPNEA (persistent, progressive, worse with exercise)
*chronic cough that may be productive,
*recurrent infections
*patients often underreport symptoms

44
Q

COPD - physical exam findings

A

*PE is rarely diagnostic in COPD
*lung exam: hyper-resonant, wheezing, or silent chest
*cardiac exam: distant heart sounds, especially if hyperinflation is present
*physical signs of airflow limitation

45
Q

COPD: treatment - 2 major goals

A
  1. symptom reduction (relieve symptoms, improve exercise tolerance, improve health)
  2. risk reduction (prevent progression, prevent exacerbations, reduce mortality)
46
Q

COPD: non-pharmacologic treatments

A

*SMOKING CESSATION
*vaccinations (pneumococcal and influenza, COVID)
*supplemental oxygen
*pulmonary rehabd

47
Q

COPD: pharmacologic options

A
  1. bronchodilators:
    -short acting beta agonists
    -short acting anticholinergics (ipratropium)
    -long acting anticholinergics (tiotroprium, aclidinium, umeclidinium)
    -long acting beta agonists
  2. anti-inflammatories:
    -ICS + LABA
    -PDE-4 inhibitors (roflumilast)
    -oral steroids
    -chronic azithromycin
48
Q

what genetic abnormality is associated with COPD

A

*alpha 1 antitrypsin deficiency (associated with panlobular emphysema)

49
Q

alpha 1 antitrypsin deficiency

A

*genetic abnormality that is a risk factor for COPD
*Serpin superfamily (SERPINA1 gene)
*found on chromosome 14
*functions as a protease inhibitor, primarily against neutrophils elastase

50
Q

clinical vignette clue for COPD due to alpha 1 antitrypsin deficiency

A

*COPD in someone less than 50yo
*+/- cirrhosis
*basilar emphysema (at the base of the lungs; lower lobes)

51
Q

alpha 1 antitrypsin deficiency COPD - pathophysiology

A

*neutrophils release neutrophil elastase after stimulation
*lack of A1AT allows neutrophil elastase to breakdown elastin of the lungs (“tethers”) → destruction of alveoli → emphysema
*lower lungs are more involved

52
Q

alpha 1 antitrypsin deficiency COPD - genotypes

A

*PiMM = normal
*PiZZ = severe deficiency
*PiZZ is associated with LIVER CIRRHOSIS (due to misfolded protein can’t be excreted and accumulated in liver cells)
*ALL COPD patients should be tested
*treatment: augmentation with donor A1AT

53
Q

COPD exacerbation - defined

A

*an acute change in a patient’s baseline symptoms:
-increased dyspnea compared to baseline
-more frequent cough
-increased sputum production beyond day-to-day variability
-symptoms significant enough to warrant a change in therapy

54
Q

etiologies of COPD acute exacerbation

A

*viral infections
*bacterial infections
*environmental triggers
*non-adherence to therapy
*pulmonary embolism

55
Q

severity of COPD exacerbation

A

*assess respiratory rate, mental status, accessory muscle use, and O2 response

*MILD: no respiratory failure
-RR 20-30, no accessory muscles, normal MS, responds to O2

*MODERATE: non-life-threatening respiratory failure
-RR > 30, accessory use, normal mental status, responds to O2, elevated PCO2

*SEVERE: life-threatening respiratory failure
-moderate criteria + CHANGE IN MENTAL STATUS, no O2 response, pH < 7.25

Pulmonology Exam (36 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions